Thus, our findings demonstrate the importance of TGF-β in patient outcomes across a broad spectrum of tumor types and datasets (see Supplementary Table S1 for a detailed list of the studies consulted) and in over 10,000 patients. This evidence concerns the gene TGFB1 and neoplasm.